ABSTRACT

Endovascular therapy in the acute management of ischemic stroke has become more common with technologic advances, such as easier navigation into the intracranial circulation and improved treatment efficacy with the advent of revascularization devices. This select review outlines milestones in the application of endovascular therapy in acute ischemic stroke (AIS) and offers some insight into important factors influencing the future directions of endovascular AIS treatment. In particular, we discuss the evolution of endovascular devices for AIS and how ingenuity continues to offer novel treatments. With these advances, the future of endovascular AIS treatment is promising.

GLOSSARY

AIS = acute ischemic stroke; DAC = distal access catheter; FDA = US Food and Drug Administration; HDE = humanitarian device exemption; IA = intra-arterial; IMS = Interventional Management of Stroke; IU = international units; MERCI = Mechanical Embolus Removal in Cerebral Ischemia; PMA = premarket approval; SICH = symptomatic intracerebral hemorrhage; TIMI = thrombolysis in myocardial ischemia; tPA = tissue plasminogen activator.

The concept of interventional treatment of acute ischemic stroke (AIS) is analogous to the percutaneous treatment of acute myocardial infarction in that the occlusive lesion is accessed via the vascular system and recanalization is achieved with endovascular techniques. Such an approach has become a standard treatment for acute coronary syndromes but has not achieved widespread acceptance for AIS. This is in large part due to the limitations of a single US Food and Drug Administration (FDA)–approved treatment for AIS, narrow therapeutic windows for treatment, and an immature repertoire of endovascular tools available for the neurointerventionalist. However, over the last 16 years, since FDA approval of tissue plasminogen activator (tPA), the field of stroke neurology has bridged this gap with improved imaging techniques and clinical trial design to consider endovascular treatment. This has been coupled with better navigation into the intracranial circulation with a newer generation of cerebral-specific catheters, microwires, and, ultimately, reperfusion devices.

This review evaluates and discusses the different endovascular strategies for acute ischemic stroke treatment, including the evolution of each technique over the past decade. These strategies include the following:

1. Chemical local recanalization
2. Mechanical recanalization
3. Augmentation of collateral flow or reversal of flow

CHEMICAL LOCAL RECANALIZATION

Early endovascular treatment of AIS was limited by the difficulty in achieving distal cranial access. Access into the proximal vessels (carotid and vertebral arteries) was possible, however, and medications were delivered here for thrombolysis of cerebral emboli. These preliminary reports suggested the possibility of a 75% rate of recanalization, though this was associated with 20% incidence of asymptomatic hemorrhagic conversion. In 1999, the Prolyse in Acute Cerebral Thromboembolism (PROACT) II study demonstrated safety and efficacy in the treatment of middle cerebral artery M1 and M2...
occlusions within 6 hours, with use of an intraclot infusion of prourokinase vs systemic heparinization. Recanalization was 66% in the treatment arm, compared with 18% that did translate into better functional outcomes (40% vs 25%). A similar study with some technical differences was reported from Japan before the approval of IV tPA. The study was performed with 114 patients within 6 hours of stroke onset; intra-arterial (IA) urokinase was used. The rate of partial recanalization was 74%, whereas complete recanalization was only 5%. The incidence of intracranial hemorrhage was 9%.

Prourokinase, which is no longer commercially available, was a second-generation plasminogen activator with high fibrin specificity, similar to alteplase. The next-generation thrombolytics reteplase and tenecteplase have higher plasmin specificity, and their use had been reported in small case series, but no randomized trials have been performed yet.

Desmoteplase is the newest generation of plasminogen activators and is the most potent and selective activator for fibrin-bound plasminogen. The Desmoteplase in Acute Ischemic Stroke (DIAS) trials I and II and the Dose Escalation of Desmoteplase in Acute Stroke (DEDAS) study demonstrated that a dose of up to 125 μg/kg had good recanalization rates, with lower risk of symptomatic intracerebral hemorrhage (SICH). DIAS III is a larger randomized trial conducted in Europe that has been prematurely stopped, and the results are unavailable.

BB10153 is a modified plasminogen in which the plasminogen activator receptor is replaced by the thrombin receptor. This would result in plasminogen binding to fibrin and dissolving a clot, without a need for plasminogen activator. This study is still ongoing. Similar to BB10153, V10153 is a recombinant plasminogen that is activated by thrombin. The phase II study, VAST, was halted because of a high risk of hemorrhagic complications: 3/9 (33%) in a 7.5-mg dose arm. Further trials are planned to study safety of lower dosages.

Direct delivery of a drug through microcatheter has made it possible to use plasmin in its active form, potentially providing a stronger fibrinolytic action. A recently published study showed an in vivo comparison of plasmin and tPA for clot lysis and did not show any statistically significant difference. A phase II dose escalation therapy using 20 mg, 40 mg, and 60 mg is ongoing in Europe. Microplasmin is another type of plasmin which is resistant to the effects of antiplasmin. Animal studies have shown good recanalization rates without higher incidence of intracerebral hemorrhage. A phase II trial, MITT014V, has shown promising result without increase in the risk of intracranial hemorrhage. The results were announced at a world stroke conference but have not been published yet.

Alfimeprase is a fibrolase derivative, which is a zinc containing metalloendopeptidase, and was first isolated from snake venom. It is a direct fibrinolytic that does not require plasminogen to break the clot. This was tested in the Catheter Directed Alfimeprase for Restoration of Neurologic Function and Rapid Opening of Arteries in Stroke (CARNEROS) II trial and did not improve the revascularization endpoints, but full results have not been published.

Ancrod is a fibrinogen-depleting agent isolated from snake venom that has been studied for the treatment of acute stroke. A small randomized trial has shown it reduced the number of deaths without any significant changes in the rate of intracranial hemorrhage. A large randomized trial of 500 patients did not show any significant improvement in outcome, with a trend toward higher incidence of intracerebral hemorrhage.

Adjunctive therapies with combination of thrombolytic medications with heparin and glycoprotein IIb/IIIa inhibitors have been tested in the past and are still under investigation in ongoing trials.

Adjunctive heparin. The use of heparin can potentially hasten the clot dissolution as well as prevent reocclusion, as fibrinolytic activity by thrombolytics creates a prothrombotic state. In one study, recanalization rates (81.8% vs 40%) were significantly higher in patients with high-dose heparin (100 IU/kg bolus followed by 1,000 IU/h) vs low-dose heparin (2000 IU bolus followed by 500 IU/h) but at the expense of higher rates of intracranial hemorrhage (15.4% vs 7.1%, respectively). The later protocol has been widely adapted and has been used in the ongoing Interventional Management of Stroke (IMS) III trial.

Adjunctive glycoprotein IIb/IIIa inhibitors. Use of glycoprotein IIb/IIIa inhibitors has been demonstrated in small nonrandomized trials. A larger randomized trial of 801 patients, AbSETT, was terminated prematurely. In this trial, 3 cohorts of patients were studied: patients with stroke onset <5 hours, 5 to 6 hours, and within 3 hours (wake-up strokes). No significant difference in good outcome was found in any of the cohorts. The wake-up stroke cohort did not have statistically significantly better outcomes in the placebo arm. Rates of symptomatic intracranial hemorrhages were significantly higher with abciximab than with placebo in all groups.

Future of chemical thrombolysis. A newer generation of fibrinolytics has been developed that could have more potent effects, with more selectivity for the clot and less neurotoxicity. These agents need to be tested.
Mechanical recanalization has become common in the endovascular management of AIS. The main treatment strategies include thrombectomy, suctioning, or thrombus disruption.

Angioplasty. Angioplasty had been used in cardiac atherosclerotic disease since the 1960s for minimally invasive revascularization of the coronary circulation. Initial limitations to using early angioplasty balloons for AIS intervention were their size and poor tractability into the cerebral vasculature. As technology improved, access into the intracranial circulation became more feasible, offering a chance at acute recanalization upon balloon inflation. Limited reports exist on the primary use of balloon maceration in AIS, though this technique is commonly considered part of the elective or urgent management of severe intracranial atherosclerotic stenosis.

Arterial dissection and rupture are the biggest risks with intracranial balloon maceration, especially in AIS, when often the occluded target vessel diameter cannot be fully quantified. In addition, with this technique the source of occlusion remains in situ, or it may be pushed into an adjacent patent branch, causing a new occlusion. However, a retrospective review showed that distal fragmentation of clot had no effect on long-term outcome.

Stent placement. The first percutaneous endovascular stent was developed and tested in the 1980s. These relatively rigid balloon-mounted devices did not safely track into the cerebrovasculature. Later generations served as the basis for developing intracranial stents, as well as the use of shape-memory materials that allowed self-expanding design. This technology reconstructs the occluded vessel, reestablishing flow acutely, though with the potential dilemma of displacing occlusive material to the lumen’s side. Retrospective reports have demonstrated efficacy of acutely deployed self-expanding stents for AIS, achieving 79% acute recanalization. Temporary partial deployment of a self-expanding stent followed by reconstrainment has been described with benefit on recanalization, without the actual implantation of the stent.

Long-term safety of endoluminal implants is not fully understood. Also, their intravascular implantation necessitates the use of antithrombotic medications, which can increase the likelihood of hemorrhagic conversion of completed AIS.

Thrombectomy and mechanical thrombus dissolution. Devices designed for thrombectomy and thrombus dissolution may have an advantage over primary angioplasty for AIS, in that they help to reduce the burden of material at the site of proximal occlusion. Although many different device configurations have been described and tested, focus here will remain on the most widely used techniques.

FDA-approved intracranial clot retrievals. The Merci Concentric Retriever (Concentric Medical, Inc., Mountainview, CA) is the first FDA-approved (2004) embolectomy device for AIS. Three generations of Merci exist. The first generation (X5 and X6) contained a tapered nitinol coil loop. The second generation (L4, L5, and L6) added monofilaments on nontapered loops for better catchment of the clot. The third generation has variable pitch loops with monofilaments (V4, V5, and V6) and is available in soft and firm categories. The recommended system is a Merci balloon guide catheter with a 2.4F delivery catheter and an optional 4.3F distal access catheter.

The Mechanical Embolus Removal in Cerebral Ischemia (MERCi) trial demonstrated a recanaliza-
tion rate (thrombolysis in myocardial ischemia [TIMI] scores of 2 and 3 [TIMI2 and TIMI3]) of 46% by device alone and 60.8% by combination of the device and chemical thrombectomy. SICH occurred in 7.8% (X series).21 The Multi-MERCI trial further evaluated the safety efficacy of the first-generation device and collected safety and technical data for second-generation devices (X and L series). The recanalization rates went up to 52% by device alone and 68% by device and tPA combination; SICH occurred in 9.8% of patients. These improvements were attributed to enhanced experience with using a device and modification in design. Because patients receiving IV tPA without recanalization were also included, this trial showed safety of Merci retrieval post-thrombolysis.22

Penumbra (Penumbra, Inc., Alameda, CA) is the other FDA-approved intracranial clot retrieval. This is a flexible catheter system connected to a vacuum pump, which suctions the thrombus into the catheter. A microwire-based separator then helps clear pieces of thrombus that could occlude the distal catheter. The pilot Penumbra trial included 20 patients, with excellent recanalization rates. The larger Penumbra stroke trial enrolled 125 patients, with an 81.6% rate of recanalization. Symptomatic hemorrhage occurred in 11.2%.

With recent modifications, 4 sizes are available: 0.054, 0.041, 0.032, and 0.026; these can be used according to the vessel size. Improvements to the aspiration capacity of the catheter, as well as modifications to improve the separator wire’s efficiency, are underway.23

Figure 1 shows different sizes of Penumbra catheters and separators.

Other clot retrievers. Multiple other devices exist that are FDA-approved to remove a foreign body but not specifically from the brain. Use of these devices has been described in case reports and case series.

Neuronet (Guidant, Santa Clara, CA) is an FDA-approved body retrieval device with a nitinol basket. It is hard to navigate it around tortuous vessels, but it can be useful for straight vessels. Its efficacy in retrieving intracranial clots has been described in case reports and a small European trial (Neuronet Evaluation in Embolic Stroke Disease [NEED]).24

Catch (Balt; Montmorency, France) is a self-expanding basket device that has been used for clot removal from the brain. A small animal study compared Catch with Merci and found them to be equally effective.25 Recent case series of patients showed a recanalization rate of 65%, with SICH occurring in 18%.26

The Phoenix Clot Retriever (Phoenix GmbH, Bochum, Germany) is a brush-like retrieval device that is deployed into the clot with a 0.021 or 0.027 microcatheter. It has a flexible nitinol/platinum alloy wire with polyamide monofilament radiating outwards. Initial case studies showed it was safe and effective, but it was never tested in a large randomized trial. The newly modified Phoenix clot retriever cage version has a small cage at the proximal end of the brush. Animal model success was recently published, showing a complete recanalization rate of 86.7% in 15 studied vessels. In a recently treated group of 48 patients, the reported recanalization rate was 56.3%.27,28

The Alligator Retrieval Device (Chestnut Medical, Menlo Park, CA) has been approved by the FDA for endovascular removal of foreign bodies and has been used to remove intracranial clots.29 Similarly, TriSpan (Boston Scientific, Natick, MA) and EnSnare (Merit Medical, Salt Lake City, UT) are not FDA-approved devices for clot removal, but off-label use has been reported. TriSpan is no longer marketed in the United States.

The AngioJet system (Possis Medical, MN) is a thrombo-aspiration device that creates distal Venturi suction from a pulsed high-pressure saline jet. It has been successfully used for peripheral and coronary clots, but because of the lack of ability to track in brain vessels, its use is limited.30

Alternative strategies for delivering energy to the site of intracranial thrombus are suggested to facilitate thrombolysis and thrombus disintegration. The Ekos MicroLysUS catheter (EKOS Corp., Bothell, WA) provides ultrasound adjuntively to systemic pharmacologic thrombolysis. Preliminary data suggest approximately 80% recanalization in less than 1 hour; further evaluation is pending as part of the IMS III trial.31 Others have attempted to dispose laser energy at the site of intracranial occlusion, but...
that has been taken out of US markets. Along with the size-related limiting of these applications for AIS, the impartation of heat energy may be deleterious.

Future of mechanical devices. Stent retrievers. The use of stent technology has been described in the history of endovascular treatment of stroke. Although mostly successful, it commonly comes with a problem of lack of antiplatelet activity at the time of stent deployment. The loading doses and maintenance of antiplatelet medications increase the risk for intracranial hemorrhage. With the advent of a closed-cell-design stent (Enterprise; Cordis Neurovascular, Miami, FL), it became possible to deploy the stent and resheath it, allowing temporary bypass and thrombectomy at the same time. Several case reports demonstrated the success and safety of this technique, but the possibility of unintentional deployment existed. Also, it was not possible to retrieve the stent into the guide catheter without resheathing it, which could result in clot embolization from the mouth of the microcatheter.

The first stent retriever device (Trevo; Concentric Medical) was launched in October 2010 in Europe. After animal trials, small trials in humans, and regulatory approval in Canada and Europe, the first patient was enrolled in the United States for the TREVO 2 trial in February 2011. The device consists of a stent mounted on the distal end of a microwire.

Trevo has a 10-mm proximal tapered end, a 4-mm radiopaque distal wire, and a 6-mm distal tapered end. The stent can be delivered by Trevo 18 or any microcatheter with an inner diameter of 0.21 or greater. The outward radial force varies with the size of the vessel. The stent can be retrieved into a 0.044" DAC (distal access catheter) or 0.057" DAC.

A similar device, Solitaire (EV3, Irvine, CA), has already been studied in the United States, in the SWIFT trial. SWIFT compared the recanalization and outcomes in acute stroke after treatment by Solitaire vs Merci. The trial was stopped prematurely because of a trend toward significantly greater recanalization rates with Solitaire. Both Trevo and Solitaire are now FDA approved for intracranial clot retrieval.

The 4-mm device can be delivered through a 0.021 microcatheter, whereas the 6-mm device requires a 0.027 microcatheter. Various case reports and case series have shown promising results. In a pilot study of 10 patients, the reported recanalization rates and good outcome, as defined by modified Rankin Scale scores of 0 to 2, were 90% and 45%, respectively. The recanalization rates are highest among the previously reported trials with older devices. The rate of SICH was 10%. Similar recanalization rates (95.4%; thrombolysis in cerebral infarction 2) and good outcome (50%) at 90 days were reported in another, 22-patient case series, and 100% partial recanalization was reported in a group of 11 patients treated in Austria. Brekenfeld et al. recently showed that the time to recanalization improved significantly (52.2 minutes vs 90 minutes) in the group of multimodality endovascular approach with Solitaire vs without Solitaire.

Figure 2 shows an old retrieval device, the Merci, and a new stent retrieval device, the Trevo.

Other future thrombectomy devices. Development of microwire- and microcatheter-based electromagnetic technology will allow sublocalization and concentration of systemically administered medicated particles at the site of distally oriented thrombi; this technology may additionally deliver focal energy similar to the Ekos catheter and laser-based devices, without generating deleterious heat. A modification of the separator for Penumbra was underway at the time this article was written and will soon be released. This will consist of multiple loops and wires that would break the clot and make it more amenable for suctioning. Modifications to other device designs being used currently will continue to improve ability to navigate and, at the same time, provide more efficient thrombectomy.

Collateral reperfusion. A novel approach to improving collateral flow in AIS is augmenting cerebral perfusion. The NeuroFlo balloon catheter (CoAxia, Inc., Maple Grove, MN) is an endovascular device designed to provide partial occlusion of the descending aorta, imparting flow diversion of cir-
Calculating blood to the cerebral vasculature and improvement in cerebral perfusion. Preliminary data suggest a sustained improvement in cerebral perfusion in areas of infarction and surrounding penumbra. A phase III prospective, randomized trial is recently reported and showed no difference in the primary study endpoint of good recovery at 90 days between the Neuroflo group and control cohort. The study did meet the safety endpoint. A Neuroflo catheter with a larger inner lumen is being developed, to allow concurrent IA intervention in the more proximal cerebral vasculature.

Figure 3 shows the details of the Neuroflo system.

Flow reversal. This is only experimental and has not been tested in humans. Revive Flow is the device under investigation. It requires placement of 2 balloon catheters, 1 on the arterial side and the other on the venous side. The catheters are connected to the reversal and pumping units. With inflation of the balloons, the circulation can be totally reversed to venous-arterial flow and perfuse the capillary bed distal to the clot, which then becomes proximal.

Theoretically, the retrograde flow through the region of arterial thrombus could facilitate dissolution or disruption, leading to concurrent thrombectomy.

DISCUSSION AIS can be due to multiple etiologies, which may not be readily discerned acutely on presentation to the hospital; pathology of large and small arteries or veins and metabolic derangements can be implicated; and endovascular treatment may benefit only large to medium artery processes. The table demonstrates the most common devices available today for mechanical thrombectomy in AIS; many devices are being tested at the bench and in AIS models, which may be available in the future.

The regulatory process for bringing a device from preclinical testing to daily practice can be significant, and the FDA has several pathways for evaluating new technology. The 510(k) process, or premarket notification, allows a relatively more simple approval of new devices due to their substantial equivalence in safety and efficacy to another previously approved and marketed device. Premarket approval (PMA) is necessary when the device cannot fulfill the substantially equivalent comparison and poses risk to the patient. Investigational device exemption can allow initial approval for the sake of obtaining clinical data.

<table>
<thead>
<tr>
<th>Devices</th>
<th>Company</th>
<th>FDA indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Merci</td>
<td>Concentric (now Stryker)</td>
<td>Restore neurovascular flow</td>
</tr>
<tr>
<td>Penumbra</td>
<td>Penumbra, Inc.</td>
<td>Revascularization for acute stroke</td>
</tr>
<tr>
<td>Neuronet</td>
<td>Boston Scientific</td>
<td>Not marketed</td>
</tr>
<tr>
<td>Catch</td>
<td>Guidant</td>
<td>Not marketed in United States</td>
</tr>
<tr>
<td>Phoenix clot retrieval</td>
<td>Phoenix GmbH</td>
<td>Not marketed in United States</td>
</tr>
<tr>
<td>Alligator</td>
<td>Chestnut Medical Technologies</td>
<td>Foreign body from peripheral and neural vasculature</td>
</tr>
<tr>
<td>EnSnare</td>
<td>Merit Medical System, Inc.</td>
<td>Retrieval of foreign object in cardiac circulation or hollow viscous</td>
</tr>
<tr>
<td>Ekos</td>
<td>EKOS Corporation</td>
<td>Infusion of fluid in peripheral vasculature</td>
</tr>
<tr>
<td>Angiojet/Neurojet</td>
<td>Possis</td>
<td>No longer marketed</td>
</tr>
<tr>
<td>Solitaire</td>
<td>EV3</td>
<td>Approved for intracranial clot removal</td>
</tr>
<tr>
<td>Trevo</td>
<td>Concentric (now Stryker)</td>
<td>Approved for Intracranial clot removal</td>
</tr>
</tbody>
</table>

Abbreviation: FDA = US Food and Drug Administration.
on safety and efficacy to support pursuit of a 510(k) or PMA. Humanitarian device exemption (HDE) is granted when a device is used for a specific condition in fewer than 4,000 individuals annually in the United States at centers with an institutional review board. HDEs are exempt from requirements to demonstrate effectiveness but must pose no unreasonable risks, or at least the probable benefits should outweigh the risks. At the time of 510(k), PMA, or HDE approval, the FDA can stipulate the requirement of postmarket studies.

The approval of multiple devices has added a challenge to the completion of multicenter trials such as IMS III.

There are several important factors for the success of an endovascular device in treating AIS. Success requires a balance of treatment by optimizing the SET triad of Safety, Efficacy, and Technical feasibility, or ease of use to allow rapid application. As new devices emerge and the treatment strategies become more refined, further improvement in efficacy can be seen for endovascular therapy for AIS. Safety will constantly be monitored as new devices are brought to the market and tested for efficacy in AIS. Only the devices that allow for easy application, with proven benefit on morbidity and mortality, will endure as part of the arsenal for the endovascular management of AIS.

AUTHOR CONTRIBUTIONS
Each author participated in writing and editing the manuscript.

DISCLOSURE
Dr. Taqi, Dr. Vora, and Dr. Callison report no disclosures. Dr. Wolfe holds a patent for a wire shaping device and catheter support system. Go to Neurology.org for full disclosures.

Received October 21, 2011. Accepted in final form January 17, 2012.

REFERENCES
tomy for acute ischemic stroke: final results of the multi 
23. Penumbra Pivotal Stroke Trial Investigators. The penumbra 
pi votal stroke trial: safety and effectiveness of a new gener-
ation of mechanical devices for clot removal in intracranial 
24. Fussell D, Schumacher HC, Meyers PM, Higashida RT. 
Mechanical interventions to treat acute stroke. Curr Neu-
thromboembolec tomy for acute ischemic stroke: compari-
on of the Catch thrombectomy device and the Merci re-
thrombectomy in acute ischemic stroke: Catch device. 
mechanical clot retrieval from intracranial arteries (pheno-
ation of the phenox CRC mechanical thrombectomy device 
in a swine model of acute vessel occlusion. AJNR Am J 
29. Kerber CW, Wanke I, Bernard Jr, Woo HH, Liu MW, 
Nelson PK. Rapid intracranial clot removal with a new 
device: the alligator retriever. AJNR Am J Neuroradiol 
30. Bellon RJ, Putman CM, Budzik RF, Pergolizzi RS, Reink-
ing GF, Norbash AM. Rheolytic thrombectomy of the oc-
cluded internal carotid artery in the setting of acute 
530.
can clinical experience with the Ekos MicroLysUS infusion 
catheter for the treatment of embolic stroke. AJNR Am J 
thrombolysis in acute ischemic stroke with endovascular 
1116.
thrombectomy with the solitaire AB device in large artery 
occlusions of the anterior circulation: a pilot study. Stroke 
2010;41:1836–1840.
34. Roth C, Papanagiotou P, Behnke S, et al. Stent-assisted 
mechanical recanalization for treatment of acute intracere-
35. Wehrschuetz M, Wehrschuetz E, Augustin M, Niederkorn 
K, Deutschmann H, Ebner F. Early single center experi-
ence with the solitaire thrombectomy device for the treat-
ment of acute ischemic stroke. Interv Neuroradiol 2011; 
17:235–240.
retrievable stents on acute ischemic stroke treatment. 
37. Liebeskind DS. Aortic occlusion for cerebral ischemia: 
from theory to practice. Curr Cardiol Rep 2008;10: 
31–36.
38. Shuaib A, Bornstein NM, Diener HC, et al. Partial aortic 
occlusion for cerebral perfusion augmentation: safety and 
efficacy of NeuroFlo in acute ischemic stroke trial. Stroke 
39. Nogueira RG, Schwamm LH, Hirsch JA. Endovascular 
approaches to acute stroke, part 1: drugs, devices, and data. 
Past, present, and future of endovascular stroke therapies
M.A. Taqi, N. Vora, R.C. Callison, et al.
Neurology 2012;79;S213-S220
DOI 10.1212/WNL.0b013e31826959e5

This information is current as of September 24, 2012

<table>
<thead>
<tr>
<th>Updated Information &amp; Services</th>
<th>including high resolution figures, can be found at: <a href="http://n.neurology.org/content/79/13_Supplement_1/S213.full">http://n.neurology.org/content/79/13_Supplement_1/S213.full</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>References</td>
<td>This article cites 39 articles, 29 of which you can access for free at: <a href="http://n.neurology.org/content/79/13_Supplement_1/S213.full#ref-list-1">http://n.neurology.org/content/79/13_Supplement_1/S213.full#ref-list-1</a></td>
</tr>
<tr>
<td>Subspecialty Collections</td>
<td>This article, along with others on similar topics, appears in the following collection(s):</td>
</tr>
<tr>
<td></td>
<td>All Cerebrovascular disease/Stroke <a href="http://n.neurology.org/cgi/collection/all_cerebrovascular_disease_stroke">http://n.neurology.org/cgi/collection/all_cerebrovascular_disease_stroke</a></td>
</tr>
<tr>
<td></td>
<td>Embolism <a href="http://n.neurology.org/cgi/collection/embolism">http://n.neurology.org/cgi/collection/embolism</a></td>
</tr>
<tr>
<td></td>
<td>Infarction <a href="http://n.neurology.org/cgi/collection/infarction">http://n.neurology.org/cgi/collection/infarction</a></td>
</tr>
<tr>
<td></td>
<td>Intracerebral hemorrhage <a href="http://n.neurology.org/cgi/collection/intracerebral_hemorrhage">http://n.neurology.org/cgi/collection/intracerebral_hemorrhage</a></td>
</tr>
<tr>
<td>Permissions &amp; Licensing</td>
<td>Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://www.neurology.org/about/about_the_journal#permissions">http://www.neurology.org/about/about_the_journal#permissions</a></td>
</tr>
<tr>
<td>Reprints</td>
<td>Information about ordering reprints can be found online: <a href="http://n.neurology.org/subscribers/advertise">http://n.neurology.org/subscribers/advertise</a></td>
</tr>
</tbody>
</table>